Home › Products › Oncology › Oncolet 2.5mg Tablet
Oncolet 2.5mg Tablet
Salt Composition: LETROZOLE
- Manufacturer: ZYDUS CADILA
- Pack Size: 10 TABLET(s) IN A STRIP
- Dosage Form: TABLET
- Strength: 2.5MG
- Prescription Required
- Storage: keep the tablets away from the reach of children and pets. Store Oncolet 2.5mg Tablets at an optimal temperature not exceeding 25°C.
₹62.00₹75.50
Inclusive of all taxes
Product Introduction
Oncolet 2.5mg is an anti-cancer medication belonging to the aromatase inhibitor class. It is indicated as adjuvant therapy following primary treatment, or as first-line therapy, for postmenopausal women with early-stage and advanced breast cancer with hormone receptor-positive tumours. Elevated oestrogen levels are associated with breast cancer development; this medicine reduces female reproductive hormone levels by inhibiting aromatase, the enzyme responsible for oestrogen production. The medication aims to slow or halt tumour growth and prevent spread to other body sites. Inform your physician if you have not yet attained menopause, as this medicine is not effective in premenopausal women. Because this medicine reduces female reproductive hormone levels, it is not recommended for menstruating women due to associated fertility concerns. Monitor your cholesterol levels regularly, as this medicine may elevate cholesterol. Oncolet 2.5mg may also decrease bone mineral density; discuss with your physician and consider regular monitoring of bone parameters. Effective contraception is advised during treatment and for at least 3 weeks after the final dose.
Uses
First and second-line treatment of postmenopausal women with hormone receptor-positive breast cancer. Supportive to standard treatment for postmenopausal women with early breast cancer. Treatment for unknown advanced breast cancer in postmenopausal women. Extended supportive therapy for postmenopausal women with early breast cancer who have already taken other anti-cancer medication.
How it works
The growth of some cancers in breasts is stimulated by estrogens. Oncolet 2.5mg Tablet is a nonsteroidal compound that inhibits estrogen production by blocking the enzyme aromatase. This medicine reduces the tumor size and stops or slows the progression of the disease, avoiding the reoccurring of early-stage breast cancer and improving the survival rate.
How to Use
It is advised to consume the medicine exactly as your doctor prescribes. It can be consumed with or without food and should be swallowed with a glass of water. Oncolet 2.5mg can be taken with or without food. It is better to take the tablet at a fixed time. Do not break, chew or crush the tablet.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Serious Decreased red blood cells Decreased bone mineral density Fluid build up in lungs Common: Swelling in the face, eyes, feet, and legs Hot sweats and excessive sweating Hypercholesterolemia (high cholesterol) Constipation Heart palpilation Hypertension Diarrhea Loss of appetite Nausea and Vomiting Muscle pain, bone pain, and joint stiffness Dizziness, tiredness, and sleepiness Breathing difficulty Arthralgia
Expert Tips
Notify your doctor if you have osteoporosis or bone fractures, as this medication is contraindicated for these conditions. Regular monitoring of bone mineral density is necessary while using Oncolet 2.5mg tablet. Discuss with your doctor if you are planning a pregnancy or have not yet gone through menopause, as it may affect fertility. Inform your doctor of any sugar intolerance, as the tablet contains lactose ingredients. If you miss a dose, do not double dose; instead, resume your regular schedule.
References
- Cipla (EU) Limited, Electronic Medicines Compendium (EMC), [Revised on Oct 2021], [Accessed on 22th Mar 2023], https://www.medicines.org.uk/emc/files/pil.9957.pdf
- Novartis Pharmaceuticals Corporation, [Revised on May 2020], [Accessed on 22th Mar 2023], https://www.novartis.us/sites/www.novartis.us/files/Femara.pdf?TB_iframe=true
- Highlights of prescribing information. (n.d.), US Food and Drug Administration [Accessed on 22th Mar 2023]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020726s027lbl.pdf
- Edward Chu, Cancer Chemotherapy, Langeâs Basic and Clinical Pharmacology, 14th Edition, 2018, 948-976.
- KD Tripathi, Estrogens, Progestins and Contraceptives, Essentials of Medical Pharmacology, 8th Edition, 2019, 330-353.
Safety Advice
Pregnancy: unsafe Oncolet 2.5mg tablet are highly unsafe during pregnancy because they may cause harm to the unborn baby. Discuss with your doctor about effective contraceptive methods. It is recommended to consult your physician if you are pregnant or may be pregnant.
Lungs: Consult your doctor Inform your physician if you have liver disease, as the Oncolet 2.5mg tablet is not recommended for patients with severe liver disease. Dose adjustment may be required.
Breastfeeding: unsafe It is unsafe to breastfeed your baby when taking Oncolet 2.5mg tablet. It is advised to avoid breastfeeding for at least three weeks after the last dose of the medicine.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.